Show Summary Details
Page of

Histiocytoses 

Histiocytoses

Chapter:
Histiocytoses
Author(s):

D.K.H Webb

DOI:
10.1093/med/9780199204854.003.220407
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2015. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy).

date: 28 April 2017

The histiocytoses are characterized by the infiltration of affected tissues with cells of monocyte/macrophage lineage.

Disorders of dendritic cells

Langerhans’ cell histiocytosis—may present with (1) disease affecting a single organ—typically skin (rash) or bone (pain and soft tissue swelling, or asymptomatic radiographic lesions); or (2) multisystem disease—characteristic features include ear discharge, diabetes insipidus, and lung involvement (diffuse micronodular shadowing on chest radiography, with progression to cyst formation and a honeycomb lung appearance). Diagnosis requires identification of Langerhans’ cells within lesional inflammatory cell infiltrate, with demonstration of either the CD1a surface antigen on immunohistochemistry or the presence of Birbeck granules on electron microscopy. Most cases eventually resolve spontaneously. Immunosuppressive and/or cytotoxic drugs are given when there is progressive organ injury, but the most effective and least toxic approach to treatment is not known.

Disorders of macrophages

Haemophagocytic lymphohistiocytosis—this may be (1) primary—an autosomal recessive disorder, caused in some cases by mutation in one of several genes involved in down-regulation of the T-cell response via apoptosis; or (2) secondary—the condition may be associated with a range of infectious, malignant and other disorders. Manifestations include fever, a variety of neurological conditions, splenomegaly, hepatomegaly, lymphadenopathy, pancytopenia, abnormal liver function, and coagulopathy. Diagnosis requires histopathological demonstration of haemophagocytosis in an appropriate clinical context. Aside from supportive care, standard treatment of primary disease is with (1) etoposide and corticosteroids, or (2) antithymocyte globulin, corticosteroids, and ciclosporin.

Malignant histiocyte disorders

Acute myelomonocytic and acute monocytic leukaemia—see Chapter 22.3.4.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.